HRP20120499T1 - Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila - Google Patents
Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila Download PDFInfo
- Publication number
- HRP20120499T1 HRP20120499T1 HRP20120499TT HRP20120499T HRP20120499T1 HR P20120499 T1 HRP20120499 T1 HR P20120499T1 HR P20120499T T HRP20120499T T HR P20120499TT HR P20120499 T HRP20120499 T HR P20120499T HR P20120499 T1 HRP20120499 T1 HR P20120499T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- amino
- wetting agent
- active ingredient
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title abstract 2
- YDXRTTNWFOUFQF-UHFFFAOYSA-N C(#N)C=CC1=CC(=C(C(=C1)C)C=1C(=C(C(=C(C#N)C1)C1=NC=CC=N1)N)N)C Chemical compound C(#N)C=CC1=CC(=C(C(=C1)C)C=1C(=C(C(=C(C#N)C1)C1=NC=CC=N1)N)N)C YDXRTTNWFOUFQF-UHFFFAOYSA-N 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000000080 wetting agent Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Kruti farmaceutski pripravak za oralno davanje naznačen time da sadrži farmaceutski prihvatljiv nosač te kao aktivni sastojak terapeutski učinkovitukoličinu spoja formule I njegov N oksid ili stereokemijski izomerni oblik te dodatno sadrži sredstvo za vlaženje Patent sadrži još patentnih zahtjeva
Claims (8)
1. Kruti farmaceutski pripravak za oralno davanje naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak terapeutski učinkovitu količinu spoja formule (I)
[image]
njegov N-oksid ili stereokemijski izomerni oblik, te dodatno sadrži sredstvo za vlaženje.
2. Farmaceutski pripravak prema zahtjevu 1 naznačen time da spoj formule (I) je spoj formule (I-a)
[image]
3. Farmaceutski pripravak prema zahtjevu 1 ili 2 naznačen time da je sredstvo za vlaženje Tween.
4. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3 naznačen time da bazirano na ukupnoj težini pripravka ima slijedeći težinski sastav:
(a) od 5 do 50% aktivnog sastojka;
(b) od 0.01 do 5 % sredstva za vlaženje;
(c) od 40 do 92% sredstva za razrjeđivanje;
(d) od 0.1 do 5% glidanta.
5. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je pripravak u obliku tablete.
6. Farmaceutski pripravak prema zahtjevu 5 naznačen time da je prevučen sa filmom.
7. Farmaceutski pripravak prema zahtjevu 5 naznačen time da bazirano na ukupnoj težini jezgre tablete ima slijedeći težinski sastav:
(a) od 5 do 50% aktivnog sastojka;
(b) od 0.01 do 5 % sredstva za vlaženje;
(c) od 40 do 92% sredstva za razrjeđivanje;
(d) od 0 do 10 % polimera;
(e) od 2 do 10 % sredstva za raspadanje;
(f) od 0.1 do 5% glidanta;
(g) od 0.1 do 1.5 % lubrikanta.
8. Uporaba farmaceutskog pripravka prema bilo kojem od prethodnih zahtjeva naznačena time da je za proizvodnju lijeka za liječenje ili sprečavanje HIV infekcije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| EP05101447 | 2005-02-25 | ||
| PCT/EP2005/054341 WO2006024667A1 (en) | 2004-09-02 | 2005-09-02 | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120499T1 true HRP20120499T1 (hr) | 2012-07-31 |
Family
ID=38091631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120499TT HRP20120499T1 (hr) | 2004-09-02 | 2012-06-14 | Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20090215804A1 (hr) |
| JP (1) | JP4922937B2 (hr) |
| AT (1) | ATE550074T1 (hr) |
| BR (1) | BRPI0514861A (hr) |
| CR (1) | CR9032A (hr) |
| DK (1) | DK1789139T3 (hr) |
| EA (1) | EA011036B1 (hr) |
| ES (1) | ES2384715T3 (hr) |
| HK (1) | HK1112862A1 (hr) |
| HR (1) | HRP20120499T1 (hr) |
| IL (1) | IL181649A0 (hr) |
| MX (1) | MX2007002594A (hr) |
| NI (1) | NI200700069A (hr) |
| NO (1) | NO339788B1 (hr) |
| SI (1) | SI1789139T1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012147091A2 (en) | 2011-04-25 | 2012-11-01 | Hetero Research Foundation | Process for rilpivirine |
| BR112022006296A2 (pt) * | 2019-10-10 | 2022-06-28 | Axcella Health Inc | Formulações de volume reduzido incluindo entidades de aminoácidos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| KR101086678B1 (ko) * | 2002-08-09 | 2011-11-25 | 얀센 파마슈티카 엔.브이. | 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법 |
| AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| ES2598404T3 (es) * | 2003-02-07 | 2017-01-27 | Janssen Pharmaceutica Nv | Derivados de pirimidina para la prevención de infección por el VIH |
-
2005
- 2005-09-02 AT AT05779369T patent/ATE550074T1/de active
- 2005-09-02 SI SI200531539T patent/SI1789139T1/sl unknown
- 2005-09-02 EA EA200700534A patent/EA011036B1/ru unknown
- 2005-09-02 JP JP2007528885A patent/JP4922937B2/ja active Active
- 2005-09-02 MX MX2007002594A patent/MX2007002594A/es active IP Right Grant
- 2005-09-02 BR BRPI0514861-8A patent/BRPI0514861A/pt not_active Application Discontinuation
- 2005-09-02 ES ES05779369T patent/ES2384715T3/es active Active
- 2005-09-02 DK DK05779369.7T patent/DK1789139T3/da active
- 2005-09-02 US US11/574,452 patent/US20090215804A1/en not_active Abandoned
-
2007
- 2007-03-01 IL IL181649A patent/IL181649A0/en active IP Right Grant
- 2007-03-01 NI NI200700069A patent/NI200700069A/es unknown
- 2007-03-30 CR CR9032A patent/CR9032A/es not_active Application Discontinuation
- 2007-04-02 NO NO20071720A patent/NO339788B1/no unknown
-
2008
- 2008-02-20 HK HK08101831.3A patent/HK1112862A1/xx unknown
-
2011
- 2011-03-04 US US13/040,465 patent/US20110150996A1/en not_active Abandoned
-
2012
- 2012-06-14 HR HRP20120499TT patent/HRP20120499T1/hr unknown
-
2017
- 2017-12-22 US US15/852,181 patent/US20180116964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR9032A (es) | 2009-07-30 |
| JP2008511591A (ja) | 2008-04-17 |
| US20110150996A1 (en) | 2011-06-23 |
| NO20071720L (no) | 2007-04-02 |
| EA200700534A1 (ru) | 2007-08-31 |
| JP4922937B2 (ja) | 2012-04-25 |
| NO339788B1 (no) | 2017-01-30 |
| DK1789139T3 (da) | 2012-07-09 |
| US20180116964A1 (en) | 2018-05-03 |
| EA011036B1 (ru) | 2008-12-30 |
| US20090215804A1 (en) | 2009-08-27 |
| ATE550074T1 (de) | 2012-04-15 |
| MX2007002594A (es) | 2007-04-25 |
| IL181649A0 (en) | 2007-07-04 |
| HK1112862A1 (hr) | 2008-09-19 |
| SI1789139T1 (sl) | 2012-08-31 |
| NI200700069A (es) | 2015-12-10 |
| ES2384715T3 (es) | 2012-07-11 |
| BRPI0514861A (pt) | 2008-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| RS52922B (en) | PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES | |
| RS51923B (en) | SO 4 [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRILA | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| AR024227A1 (es) | Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas | |
| RS54187B1 (en) | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| MY147373A (en) | Piperazine derivatives as antimalarial agents | |
| RU2008113439A (ru) | Композиции с замедленным высвобождением лекарственного средства | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| NO20081325L (no) | Nye doseringsformuleringer | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| TW200607508A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| SE9901573D0 (sv) | New compounds | |
| HRP20110436T1 (hr) | Supstituirani karboksamidi kao antagonisti metabotropnih receptora iz skupine i | |
| HRP20120257T1 (hr) | Antagonisti receptora 5-ht7 | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| CA2437785A1 (en) | Hiv inhibiting pyrazinone derivatives | |
| HRP20120499T1 (hr) | Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila | |
| JP2019510834A5 (hr) | ||
| WO2007065625A3 (en) | Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations | |
| HRP20240118T1 (hr) | Disperzivni pripravci | |
| JP2020500168A5 (hr) |